Home > Healthcare > Pharmaceuticals > Finished Drug Form > Buccal Drug Delivery Systems Market

Buccal Drug Delivery Systems Market Share

Report ID: GMI10233
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Buccal Drug Delivery Systems Market Share

The buccal drug delivery systems sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovations such as advanced mucoadhesive buccal systems, buccal films and tablets with advanced formulations, nano-enhanced buccal delivery systems, and bio-responsive buccal drug delivery systems. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Buccal Drug Delivery Systems Market Companies

Some of the eminent market participants operating in the buccal drug delivery systems industry include:

AbbVie Inc.
Amgen Inc.
Collegium Pharmaceutical, Inc.
Endo International plc
Galderma SA
Indivior plc
Johnson & Johnson Services, Inc.
Kyowa Kirin Co., Ltd.
Mallinckrodt plc
Neurelis, Inc.
Novartis AG
Pfizer Inc.
Sanofi
Takeda Pharmaceuticals Company Limited
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The buccal drug delivery systems market size was valued at USD 3.9 billion in 2023 and is estimated to grow at 8.6% CAGR from 2024 to 2032 due to rising prevalence of chronic diseases and the presence of supportive regulatory landscape.

The buccal films segment in the market recorded a revenue of USD 1.6 billion in 2023, owing to the growing demand for non-invasive and patient-centric drug delivery solutions.

North America buccal drug delivery systems market is forecasted to reach USD 3.2 billion by 2032, propelled by technological advancements, heightened public awareness, and the rising prevalence of chronic diseases.

AbbVie Inc., Amgen Inc., Collegium Pharmaceutical, Inc., Endo International plc, Galderma SA, Indivior plc, Johnson & Johnson Services, Inc., Kyowa Kirin Co., Ltd., Mallinckrodt plc, Neurelis, Inc., and Novartis AG among others.